MCP
PFE icon

Moab Capital Partners’s Pfizer PFE Stock Holding History

Moab Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-172,092
Closed -$5.3M – 31
2016
Q4 		$5.3M Hold
172,092
– – 1.77% 14
2016
Q3 		$5.53M Sell
172,092
-2,319
-1% -$77.5K 1.8% 13
2016
Q2 		$5.83M Buy
174,411
+1,204
+0.7% +$38.4K 1.85% 13
2016
Q1 		$4.87M Buy
+173,207
New +$4.95M 1.7% 14

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Moab Capital Partners's PFE Position: Q1 2017 in Review

Moab Capital Partners sold out of Pfizer (PFE) in Q1 2017, closing a stake of 172,092 shares — an estimated $5.3M sold.

Moab Capital Partners first reported a position in PFE in Q1 2016 and held it in 4 quarters. The position peaked at $5.83M in Q2 2016. 2,075 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

  • Moab Capital Partners reported no remaining Pfizer position as of Q1 2017 after selling out during the quarter.
  • Moab Capital Partners sold 172,092 Pfizer shares in Q1 2017, an estimated $5.3M.
  • Moab Capital Partners first reported a position in Pfizer in Q1 2016 and held it in 4 quarters.
  • Moab Capital Partners's Pfizer position peaked at $5.83M in Q2 2016.
  • 2,075 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on Moab Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.